Abstract

The surface proteins of the mumps virus, the fusion protein (F) and haemagglutinin-neuraminidase (HN), are key factors in mumps pathogenesis and are important targets for the immune response during mumps virus infection. We compared the predicted amino acid sequences of the F and HN genes from Dutch mumps virus samples from the pre-vaccine era (1957–1982) with mumps virus genotype G strains (from 2004 onwards). Genotype G is the most frequently detected mumps genotype in recent outbreaks in vaccinated communities, especially in Western Europe, the USA and Japan. Amino acid differences between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein. There were eight variable amino acid positions specific to genotype A or genotype G sequences in five known B-cell epitopes of the HN protein. These differences may account for the reported antigenic differences between Jeryl Lynn and genotype G strains. We also found amino acid differences in and near sites on the HN protein that have been reported to play a role in mumps virus pathogenesis. These differences may contribute to the occurrence of genotype G outbreaks in vaccinated communities.

Details

Title
Differences in antigenic sites and other functional regions between genotype A and G mumps virus surface proteins
Author
Gouma Sigrid 1 ; Vermeire Tessa 2 ; Van Gucht Steven 3   VIAFID ORCID Logo  ; Martens Lennart 4 ; Veronik, Hutse 3 ; Cremer Jeroen 5 ; Rota, Paul A 6 ; Leroux-Roels Geert 7 ; Koopmans, Marion 8 ; van Binnendijk Rob 5 ; Elien, Vandermarliere 4 

 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands (GRID:grid.31147.30) (ISNI:0000 0001 2208 0118); Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); University of Pennsylvania, Microbiology Department, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 Sciensano, National Reference Centre for Measles, Mumps and Rubella, Brussels, Belgium (GRID:grid.25879.31); Ghent University, Department of Biochemistry, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040) 
 Sciensano, National Reference Centre for Measles, Mumps and Rubella, Brussels, Belgium (GRID:grid.11486.3a) 
 Ghent University, Department of Biochemistry, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040) 
 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands (GRID:grid.31147.30) (ISNI:0000 0001 2208 0118) 
 Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, Atlanta, USA (GRID:grid.416738.f) (ISNI:0000 0001 2163 0069) 
 Ghent University, Center for Vaccinology, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798) 
 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands (GRID:grid.31147.30) (ISNI:0000 0001 2208 0118); Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X) 
Publication year
2018
Publication date
Dec 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2100355050
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.